38825-85-3

Usage

InChI:InChI=1/C6H15NO/c1-2-4-7-5-3-6-8/h7-8H,2-6H2,1H3

Upstream product

• 107-10-8 propylamine 
• 20907-32-8 sodium allyloxide 
• 107-18-6 allyl alcohol 
• 627-18-9 1-bromo-3-propanol 
• 38825-84-2 Propylaminopropylacetat 
• 627-30-5 1-chloro-3-hydroxypropane 
• 503-30-0 trimethylene oxide 
• 124-38-9 carbon dioxide 
• 123-38-6 propionaldehyde 
• 156-87-6 propan-1-ol-3-amine 
• 142-84-7 di-n-propylamine 

Downstream Products

• 28242-03-7 p-(N-Propyl-N-3-hydroxypropylsulfamoyl)benzoesaeure 
• 40911-00-0 N-propyl-N-(3-hydroxypropyl)nitrosamine 
• 1384958-71-7 (1E,4E)-N-(3-(tert-butyldimethylsilyloxy)propyl)-2-(2-(dimethylamino)ethylamino)-N-propyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide 
• 1384958-41-1 (1E,4E)-2-(2-(dimethylamino)ethylamino)-N-(3-hydroxypropyl)-N-propyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide 
• 1384958-74-0 (1E,4E)-N-(3-(tert-butyldimethylsilyloxy)propyl)-2-(methylamino)-N-propyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide 
• 1384958-43-3 (1E,4E)-N-(3-hydroxypropyl)-2-(methylamino)-N-propyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide 
• 1268163-51-4 tert-butyl (1E,4E)-4-((3-(tert-butyldimethylsilyloxy)propyl)(propyl)carbamoyl)-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepin-2-ylcarbamate 

Relevant academic research and scientific papers

AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY

An azaaryl derivative with the structure of formula (I), a preparation method therefor and a pharmaceutical use thereof are disclosed in the present invention. The series of compounds of the present invention can be widely applied in the preparation of dr

Benzazepine Dicarboxamide Compounds

This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

Platinum-Catalyzed, Terminal-Selective C(sp3)-H Oxidation of Aliphatic Amines

This Communication describes the terminal-selective, Pt-catalyzed C(sp3)-H oxidation of aliphatic amines without the requirement for directing groups. CuCl2 is employed as a stoichiometric oxidant, and the reactions proceed in high yield at Pt loadings as low as 1 mol%. These transformations are conducted in the presence of sulfuric acid, which reacts with the amine substrates in situ to form ammonium salts. We propose that protonation of the amine serves at least three important roles: (i) it renders the substrates soluble in the aqueous reaction medium; (ii) it limits binding of the amine nitrogen to Pt or Cu; and (iii) it electronically deactivates the C-H bonds proximal to the nitrogen center. We demonstrate that this strategy is effective for the terminal-selective C(sp3)-H oxidation of a variety of primary, secondary, and tertiary amines.

Formation of 3-hydroxyalkyl carbamates from carbon dioxide, amines and oxetanes

The reactions of carbon dioxide, primary or secondary aliphatic amines and oxetanes at a CO2 pressure of 40 atm at 100-120°C without any catalysts afforded new monocarbamates of 1,3-propanediols, with concomitant formation of amino alcohols from oxetanes and amines.